Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone for Flashbacks and Dissociation in Borderline Personality Disorder
NCT00124839Phase 3Terminated
- Sponsor
- Central Institute of Mental Health
- Start
- Oct 2005
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naltrexone in borderline personality disorder (BPD) (4 arms), sponsored by Central Institute of Mental Health. Primary endpoint: Reduction of dissociative symptoms at 3 weeks. Started Oct 2005; status: terminated.
02
Drugs
naltrexone
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT00124839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124839.